BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $2,996,000 | -70.5% | 179,629 | -17.2% | 0.00% | -75.0% |
| Q3 2021 | $10,164,000 | -22.7% | 216,860 | +0.5% | 0.01% | -20.0% |
| Q2 2021 | $13,152,000 | -4.4% | 215,756 | -3.4% | 0.01% | 0.0% |
| Q1 2021 | $13,755,000 | +7.4% | 223,299 | +23.9% | 0.01% | 0.0% |
| Q4 2020 | $12,811,000 | +106.5% | 180,153 | +9.0% | 0.01% | +66.7% |
| Q3 2020 | $6,203,000 | +18.0% | 165,337 | +2.6% | 0.01% | +20.0% |
| Q2 2020 | $5,255,000 | +283.6% | 161,137 | +241.2% | 0.01% | +150.0% |
| Q1 2020 | $1,370,000 | +4.2% | 47,228 | +25.9% | 0.00% | +100.0% |
| Q4 2019 | $1,315,000 | – | 37,515 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |